Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 7/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 4/20 | 0.39 |
| ▸ | MMP1 | P03956 | 6/20 | 0.39 |
| ▸ | MMP3 | P08254 | 5/20 | 0.39 |
| ▸ | MMP9 | P14780 | 4/20 | 0.39 |
| ▸ | MMP7 | P09237 | 3/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MMP10 | P09238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7200991 | 0.92 | MMP13 (0.43) | SMN1; SMN2MAPTFPR2PROKR1MMP13 | |
| SCHEMBL7202693 | 0.91 | FPR2 (0.44) | SMN1; SMN2MAPTFPR2PROKR1MMP13 | |
| SCHEMBL7204519 | 0.90 | MMP13 (0.43) | FPR2PROKR1MMP13MMP2MMP1 | |
| SCHEMBL7202573 | 0.90 | MMP13 (0.43) | SMN1; SMN2FPR2PROKR1MMP13MMP14 | |
| SCHEMBL7199648 | 0.90 | HTR2C (0.44) | FPR2PROKR1MMP13MMP2MMP3 | |
| SCHEMBL7202610 | 0.89 | MMP13 (0.42) | SMN1; SMN2MMP13MMP14MMP2MMP1 | |
| SCHEMBL7201643 | 0.88 | MMP13 (0.41) | MMP13MMP14MMP2MMP1EPHX2 | |
| SCHEMBL7207178 | 0.88 | USP5 (0.43) | MMP13MMP2MMP1MMP3MMP9 | |
| SCHEMBL7202570 | 0.86 | EPHX2 (0.41) | MMP13MMP2MMP3MMP9EPHX2 | |
| SCHEMBL7200949 | 0.85 | MMP13 (0.45) | FPR2PROKR1MMP13MMP1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | SMN1; SMN2 2083/4885MAPT 2469/4885FPR2 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.